247 related articles for article (PubMed ID: 37123549)
1. The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.
Song K; Artibani M
Health Sci Rep; 2023 May; 6(5):e1235. PubMed ID: 37123549
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation characteristics associated with chemotherapy resistance in epithelial ovarian cancer.
Duan C; Yan Z; Wu C; Zhou X; Bao W
Heliyon; 2024 Mar; 10(5):e27212. PubMed ID: 38468944
[TBL] [Abstract][Full Text] [Related]
5. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
6. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
Gomez S; Cox OL; Walker RR; Rentia U; Hadley M; Arthofer E; Diab N; Grundy EE; Kanholm T; McDonald JI; Kobyra J; Palmer E; Noonepalle S; Villagra A; Leitenberg D; Bollard CM; Saunthararajah Y; Chiappinelli KB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36343976
[TBL] [Abstract][Full Text] [Related]
8. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
Feng LY; Yan BB; Huang YZ; Li L
Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer detection by DNA methylation in cervical scrapings.
Wu TI; Huang RL; Su PH; Mao SP; Wu CH; Lai HC
Clin Epigenetics; 2019 Nov; 11(1):166. PubMed ID: 31775891
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.
Li M; Balch C; Montgomery JS; Jeong M; Chung JH; Yan P; Huang TH; Kim S; Nephew KP
BMC Med Genomics; 2009 Jun; 2():34. PubMed ID: 19505326
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer.
Wang Y; Huang Z; Li B; Liu L; Huang C
Front Endocrinol (Lausanne); 2022; 13():863541. PubMed ID: 35620395
[TBL] [Abstract][Full Text] [Related]
12. Contribution of genetic and epigenetic mechanisms to Wnt pathway activity in prevalent skeletal disorders.
García-Ibarbia C; Delgado-Calle J; Casafont I; Velasco J; Arozamena J; Pérez-Núñez MI; Alonso MA; Berciano MT; Ortiz F; Pérez-Castrillón JL; Fernández AF; Fraga MF; Zarrabeitia MT; Riancho JA
Gene; 2013 Dec; 532(2):165-72. PubMed ID: 24096177
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
14. In silico analysis of DYNLL1 expression in ovarian cancer chemoresistance.
Berkel C; Cacan E
Cell Biol Int; 2020 Aug; 44(8):1598-1605. PubMed ID: 32208526
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.
Su HY; Lai HC; Lin YW; Liu CY; Chen CK; Chou YC; Lin SP; Lin WC; Lee HY; Yu MH
Int J Cancer; 2010 Aug; 127(3):555-67. PubMed ID: 19957335
[TBL] [Abstract][Full Text] [Related]
16. MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway.
Gu ZW; He YF; Wang WJ; Tian Q; Di W
J Zhejiang Univ Sci B; 2019 Mar.; 20(3):219-237. PubMed ID: 30829010
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer.
Matthews BG; Bowden NA; Wong-Brown MW
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885103
[TBL] [Abstract][Full Text] [Related]
18. Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.
Terp SK; Stoico MP; Dybkær K; Pedersen IS
Clin Epigenetics; 2023 Feb; 15(1):24. PubMed ID: 36788585
[TBL] [Abstract][Full Text] [Related]
19. Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer.
Niiro E; Morioka S; Iwai K; Yamada Y; Ogawa K; Kawahara N; Kobayashi H
Biomed Rep; 2018 Mar; 8(3):215-223. PubMed ID: 29564122
[TBL] [Abstract][Full Text] [Related]
20. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert C; Van Hemelrijck LA; Maes A; De Veirman K; Menu E; Vanderkerken K; De Bruyne E
Front Oncol; 2022; 12():979569. PubMed ID: 36059621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
